Jana Kasparkova

TL;DR: A number of new platinum compounds were designed to test the hypothesis that there is a correlation between the extent of resistance of tumors to these agents and their ability to induce a certain kind of damage or conformational change in DNA.

TL;DR: The trans diazido PtIV complex 1 is remarkably stable in the dark, even in the presence of cellular reducing agents, and is a candidate for use in photoactivated cancer chemotherapy.

TL;DR: XPA in conjunction with RPA may constitute a regulatory factor that monitors DNA bending and unwinding to verify the damage‐specific localization of repair complexes or control their correct three‐dimensional assembly.

TL;DR: The results point to a unique profile of DNA binding for BBR3464, strengthening the original hypothesis that modification ofDNA binding in manners distinct from that of cisplatin will also lead to a distinct and unique profileof antitumor activity.

TL;DR: Recent insights into the effects of sulfur-containing compounds on DNA modifications by antitumor platinum complexes and how these modifications are repaired including how this repair is associated with their recognition by cellular, damaged-DNA binding-proteins strongly supports the view that changes in the structure of platinum drugs, resulting in DNA binding mode fundamentally different from that of "classical" cisplatin, will alter resistance pathways and may also modulate their pharmacological properties.